Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SCN1A | P35498 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23696480 | 0.87 | ALDH1A1 (0.36) | ALDH1A1SCN1ASCN2ASCN3AEPHX2 | |
| SCHEMBL22047821 | 0.87 | ALDH1A1 (0.36) | ALDH1A1SCN1ASCN2ASCN3AEPHX2 | |
| SCHEMBL22861717 | 0.87 | ALDH1A1 (0.36) | ALDH1A1SCN1ASCN2ASCN3AEPHX2 | |
| SCHEMBL22861744 | 0.87 | ALDH1A1 (0.36) | ALDH1A1SCN1ASCN2ASCN3AEPHX2 | |
| SCHEMBL1967441 | 0.84 | ALDH1A1 (0.38) | ALDH1A1EPHX2SMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL18551601 | 0.83 | ALDH1A1 (0.41) | ALDH1A1SCN1ASCN2ASCN3AEPHX2 | |
| SCHEMBL14296394 | 0.79 | SCN1A (0.42) | ALDH1A1SCN1ASCN2ASCN3ACYP1A2 | |
| SCHEMBL18551477 | 0.79 | ALDH1A1 (0.44) | ALDH1A1SCN1ASCN2ASCN3AEPHX2 | |
| SCHEMBL25567929 | 0.78 | ALDH1A1 (0.32) | ALDH1A1EPHX2SMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL27396262 | 0.78 | ALDH1A1 (0.36) | ALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2022272248-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2021188948-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2019-03-14 | — | — | US | disclosed |
| EP-3019488-B1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-11-07 | — | — | EP | disclosed |
| US-9895330-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-20 | — | — | US | disclosed |
| US-9895330-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-20 | — | — | US | disclosed |
| US-9895330-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-20 | — | — | US | disclosed |
| US-20160143870-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-26 | — | — | US | disclosed |
| US-20160143870-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-26 | — | — | US | disclosed |
| US-20160143870-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-26 | — | — | US | disclosed |
| CN-105517999-A | Ido inhibitors | BRISTOL MYERS SQUIBB CO | 2016-04-20 | — | — | CN | disclosed |
| US-9095504-B2 | RNA interference in ocular indications | RXI PHARMACEUTICALS CORPORATION | 2015-08-04 | — | — | US | disclosed |
| WO-2015006520-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-15 | — | — | WO | disclosed |
| US-20130131142-A1 | RNA INTERFERENCE IN OCULAR INDICATIONS | PHIO PHARMACEUTICALS CORP. | 2013-05-23 | — | — | US | disclosed |
| US-20090111805-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | ALDH1A1 1804/4885SCN1A 4841/4885SCN2A 4796/4885 |
| US-20090111805-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNB1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNY | ALDH1A1 1765/4885SCN1A 4266/4885SCN2A 4725/4885 |
| US-20160143870-A1 | IDO INHIBITORS | IDO1, IDO2, TDO2 | ALDH1A1 435/4885SCN1A 4012/4885SCN2A 4217/4885 |
| US-20130131142-A1 | RNA INTERFERENCE IN OCULAR INDICATIONS | RXRA, RXRB, RXRG | ALDH1A1 1687/4885SCN1A 2698/4885SCN2A 2446/4885 |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | ALDH1A1 2571/4885SCN1A 1240/4885SCN2A 2039/4885 |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | ALDH1A1 2605/4885SCN1A 926/4885SCN2A 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.